Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9402
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a solicitation for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) as part of its ongoing efforts to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). This initiative is mandated by 10 U.S.C. § 1074g and further guided by implementing regulations (32 CFR Section 199.21), which require the DHA to evaluate pharmaceutical agents for inclusion in the Department of War (DoW) Uniform Formulary (UF).
The primary purpose of this procurement is to solicit quotations from industry for pharmaceutical agents within specific drug classes identified for potential placement on the UF. The process is closely tied to the recommendations of the DoW Pharmacy and Therapeutics (P&T) Committee, which assesses both the clinical and cost effectiveness of agents within therapeutic classes. The outcomes of this solicitation will directly influence the selection and classification of pharmaceutical agents as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF), thereby impacting cost-sharing arrangements and access for MHS beneficiaries.
For the upcoming P&T Committee meeting scheduled in November 2026, the following newly approved drugs will be reviewed for potential inclusion:
- Awiqli Flextouch (Insulin - Basal)
- Cavhanza (Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors)
- Lipfendra (Antilipidemics-1 - PCSK-9)
- Trutakna (Nephrology Agents Miscellaneous)
The solicitation, identified by procurement number HT9402-26-Q-9402, includes detailed instructions, appendices for UF BPA and UF ADP, important deadlines, and points of contact. Interested contractors are encouraged to review the attached RFQ documents for comprehensive guidance. A pre-quotation teleconference is scheduled for August 12, 2026, with specific details provided in Part 2.4 of the RFQ. Responses to clinical questions outlined in Part 3.4 must be submitted via email to the designated point of contact by the deadline specified in Part 2.3.2.
Key requirements for this opportunity include the ability to manufacture pharmaceutical preparations (NAICS Code 325412, Pharmaceutical Preparation Manufacturing), with the place of performance located in San Antonio, Texas. The solicitation is classified under Product Service Code 6505, which pertains to drugs and biologicals.
The contracting entity is the Defense Health Agency, a federal office within the Department of Defense. Primary and secondary points of contact for this procurement are Julia Trang ([email protected]) and Stephanie Erpelding ([email protected]), respectively.
This solicitation remains active, with a response deadline of August 27, 2026, at 17:08. Contractors interested in participating should ensure their capabilities align with the requirements for pharmaceutical preparation manufacturing and be prepared to engage in the UF BPA and UF ADP processes as outlined in the RFQ. The opportunity is accessible via SAM.gov (Opportunity ID: 26b1e1355c8e4f149b0b25b7d81a8316), where additional attachments and details are available.
Overall, this procurement represents a significant opportunity for pharmaceutical manufacturers to contribute to the MHS pharmacy benefits program, supporting the delivery of clinically effective and cost-efficient medications to military beneficiaries.
Documents7